<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37579081</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>16</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1469-493X</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>8</Issue><PubDate><Year>2023</Year><Month>Aug</Month><Day>10</Day></PubDate></JournalIssue><Title>The Cochrane database of systematic reviews</Title><ISOAbbreviation>Cochrane Database Syst Rev</ISOAbbreviation></Journal><ArticleTitle>Enteral tube feeding for amyotrophic lateral sclerosis/motor neuron disease.</ArticleTitle><Pagination><StartPage>CD004030</StartPage><MedlinePgn>CD004030</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">CD004030</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1002/14651858.CD004030.pub4</ELocationID><Abstract><AbstractText Label="BACKGROUND">Maintaining adequate nutrition is critical for people with amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND). Enteral tube feeding is offered to people experiencing difficulty swallowing (dysphagia) to prevent weight loss and aspiration pneumonia. Among the types of enteral tube feeding, percutaneous endoscopic gastrostomy (PEG) is the typical procedure offered to people with ALS and will be mainly discussed here.</AbstractText><AbstractText Label="OBJECTIVES">To examine the effectiveness of percutaneous endoscopic gastrostomy or other enteral tube feeding in people with ALS, compared to oral feeds without enteral tube feeding on: 1. survival; 2. nutritional status; 3. quality of life. To examine the incidence of minor and major complications of percutaneous endoscopic gastrostomy (PEG) and other enteral tube feeding procedures in people with ALS.</AbstractText><AbstractText Label="SEARCH METHODS">On 3 January 2020 and 6 February 2021, we searched the Cochrane Neuromuscular Specialised Register, CENTRAL, MEDLINE. Embase, ClinicalTrials.gov and WHO ICTRP. We screened the results to identify randomized controlled studies on enteral tube feeding in ALS. We reviewed all references from the search in published articles to identify any additional references.</AbstractText><AbstractText Label="SELECTION CRITERIA">We included randomized controlled trials (RCTs), quasi-RCTs, and cross-over trials evaluating the effectiveness and complications of PEG or other enteral tube feeding placement in ALS.</AbstractText><AbstractText Label="DATA COLLECTION AND ANALYSIS">We used standard methodological procedures expected by Cochrane.</AbstractText><AbstractText Label="MAIN RESULTS">We found no RCTs or quasi-RCTs comparing the effectiveness of enteral tube feeding versus oral feeds without enteral tube feeding.</AbstractText><AbstractText Label="AUTHORS' CONCLUSIONS">There are no RCTs or quasi-RCTs to indicate whether enteral tube feeding is effective compared to continuation of oral feeding for any of the outcome measures. Such RCTs are very unlikely to be performed for ethical reasons. RCTs evaluating the effect of different enteral tube insertion techniques and timings of tube placement on survival and quality of life of people with ALS dysphagia are feasible and warranted.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sulistyo</LastName><ForeName>Adrienne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Medical Science, University of Toronto, Toronto, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abrahao</LastName><ForeName>Agessandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Neurology, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Freitas</LastName><ForeName>Maria Eliza</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Division of Neurology, Department of Medicine, McMaster University, Hamilton, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ritsma</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Physical Medicine &amp; Rehabilitation, Queen's University, Providence Care Hospital, Kingston , Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zinman</LastName><ForeName>Lorne</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Neurology, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Cochrane Database Syst Rev</MedlineTA><NlmUniqueID>100909747</NlmUniqueID><ISSNLinking>1361-6137</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="UpdateOf"><RefSource>Cochrane Database Syst Rev. 2011 Jan 19;(1):CD004030</RefSource><PMID Version="1">21249659</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003680" MajorTopicYN="Y">Deglutition Disorders</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004750" MajorTopicYN="N">Enteral Nutrition</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007441" MajorTopicYN="N">Intubation, Gastrointestinal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016472" MajorTopicYN="Y">Motor Neuron Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="kor"><AbstractText>&#xbc30;&#xacbd;: &#xc6b4;&#xb3d9; &#xc2e0;&#xacbd; &#xc9c8;&#xd658;(MND)&#xc73c;&#xb85c;&#xb3c4; &#xc54c;&#xb824;&#xc9c4; &#xadfc;&#xc704;&#xcd95;&#xc131;&#xce21;&#xc0ad;&#xacbd;&#xd654;&#xc99d;(ALS) &#xd658;&#xc790;&#xc5d0;&#xac8c;&#xb294; &#xc801;&#xc808;&#xd55c; &#xc601;&#xc591;&#xc744; &#xc720;&#xc9c0;&#xd558;&#xb294; &#xac83;&#xc774; &#xc911;&#xc694;&#xd558;&#xb2e4;. &#xccb4;&#xc911; &#xac10;&#xc18c;&#xc640; &#xd761;&#xc778;&#xc131; &#xd3d0;&#xb834;&#xc744; &#xc608;&#xbc29;&#xd558;&#xae30; &#xc704;&#xd574; &#xc0bc;&#xd0b4; &#xace4;&#xb780;(&#xc0bc;&#xd0b4;&#xace4;&#xb780;)&#xc744; &#xacbd;&#xd5d8;&#xd558;&#xb294; &#xc0ac;&#xb78c;&#xb4e4;&#xc5d0;&#xac8c; &#xacbd;&#xc7a5; &#xc601;&#xc591;&#xc774; &#xc81c;&#xacf5;&#xb41c;&#xb2e4;. &#xacbd;&#xc7a5; &#xc601;&#xc591; &#xc911; &#xacbd;&#xd53c;&#xc801; &#xb0b4;&#xc2dc;&#xacbd;&#xc801; &#xc704;&#xb8e8;&#xc220;(PEG)&#xc740; ALS &#xd658;&#xc790;&#xc5d0;&#xac8c; &#xc81c;&#xacf5;&#xb418;&#xb294; &#xb300;&#xd45c;&#xc801;&#xc778; &#xc2dc;&#xc220;&#xc774;&#xba70; &#xc5ec;&#xae30;&#xc11c; &#xc8fc;&#xb85c; &#xb17c;&#xc758;&#xb420; &#xac83;&#xc774;&#xb2e4;. &#xbaa9;&#xc801;: ALS &#xd658;&#xc790;&#xc758; &#xacbd;&#xd53c; &#xb0b4;&#xc2dc;&#xacbd; &#xc704;&#xb8e8;&#xc220; &#xb610;&#xb294; &#xae30;&#xd0c0; &#xacbd;&#xc7a5; &#xc601;&#xc591;&#xc758; &#xd6a8;&#xacfc;&#xb97c; &#xc7a5;&#xad00; &#xc601;&#xc591;&#xc774; &#xc5c6;&#xb294; &#xacbd;&#xad6c; &#xc601;&#xc591;&#xacfc; &#xbe44;&#xad50;&#xd558;&#xc5ec;: 1. &#xc0dd;&#xc874; 2. &#xc601;&#xc591; &#xc0c1;&#xd0dc; 3. &#xc0b6;&#xc758; &#xc9c8;. ALS &#xd658;&#xc790;&#xc5d0;&#xc11c; &#xacbd;&#xd53c;&#xc801; &#xb0b4;&#xc2dc;&#xacbd; &#xc704;&#xb8e8;&#xc220;(PEG) &#xbc0f; &#xae30;&#xd0c0; &#xacbd;&#xc7a5; &#xc601;&#xc591; &#xc808;&#xcc28;&#xc758; &#xacbd;&#xbbf8;&#xd55c; &#xd569;&#xbcd1;&#xc99d; &#xbc0f; &#xc8fc;&#xc694; &#xd569;&#xbcd1;&#xc99d; &#xbc1c;&#xc0dd;&#xb960;&#xc744; &#xc870;&#xc0ac;&#xd55c;&#xb2e4;. &#xac80;&#xc0c9; &#xc804;&#xb7b5;: 2020&#xb144; 1&#xc6d4; 3&#xc77c;&#xacfc; 2021&#xb144; 2&#xc6d4; 6&#xc77c;&#xc5d0; Cochrane Neuromuscular Specialized Register, CENTRAL, MEDLINE&#xc744; &#xac80;&#xc0c9;&#xd588;&#xb2e4;. Embase, ClinicalTrials.gov &#xbc0f; WHO ICTRP. ALS&#xc5d0;&#xc11c; &#xacbd;&#xc7a5; &#xc601;&#xc591;&#xc5d0; &#xb300;&#xd55c; &#xbb34;&#xc791;&#xc704; &#xb300;&#xc870; &#xc5f0;&#xad6c;&#xb97c; &#xc2dd;&#xbcc4;&#xd558;&#xae30; &#xc704;&#xd574; &#xacb0;&#xacfc;&#xb97c; &#xc120;&#xbcc4;&#xd588;&#xb2e4;. &#xac8c;&#xc2dc;&#xb41c; &#xae30;&#xc0ac;&#xc5d0;&#xc11c; &#xac80;&#xc0c9;&#xd55c; &#xbaa8;&#xb4e0; &#xcc38;&#xc870;&#xb97c; &#xac80;&#xd1a0;&#xd558;&#xc5ec; &#xcd94;&#xac00; &#xcc38;&#xc870;&#xb97c; &#xc2dd;&#xbcc4;&#xd588;&#xb2e4;. &#xc120;&#xc815; &#xae30;&#xc900;: ALS&#xc5d0;&#xc11c; PEG &#xb610;&#xb294; &#xae30;&#xd0c0; &#xacbd;&#xc7a5; &#xc601;&#xc591;&#xc2dd; &#xc704;&#xce58;&#xc758; &#xd6a8;&#xacfc;&#xc640; &#xd569;&#xbcd1;&#xc99d;&#xc744; &#xd3c9;&#xac00;&#xd558;&#xb294; &#xbb34;&#xc791;&#xc704; &#xb300;&#xc870; &#xc2dc;&#xd5d8;(RCT), &#xc900; RCT &#xbc0f; &#xad50;&#xcc28; &#xc2dc;&#xd5d8;&#xc744; &#xd3ec;&#xd568;&#xd588;&#xb2e4;. &#xc790;&#xb8cc; &#xc218;&#xc9d1; &#xbc0f; &#xbd84;&#xc11d;: &#xcf54;&#xd06c;&#xb780;&#xc5d0;&#xc11c; &#xae30;&#xb300;&#xd558;&#xb294; &#xd45c;&#xc900; &#xbc29;&#xbc95;&#xb860;&#xc801; &#xc808;&#xcc28;&#xb97c; &#xc0ac;&#xc6a9;&#xd588;&#xb2e4;. &#xc8fc;&#xc694; &#xacb0;&#xacfc;: &#xacbd;&#xc7a5; &#xc601;&#xc591;&#xacfc; &#xacbd;&#xc7a5; &#xc601;&#xc591;&#xc744; &#xc0ac;&#xc6a9;&#xd558;&#xc9c0; &#xc54a;&#xb294; &#xacbd;&#xad6c; &#xc601;&#xc591;&#xc758; &#xd6a8;&#xacfc;&#xb97c; &#xbe44;&#xad50;&#xd558;&#xb294; RCT &#xb610;&#xb294; &#xc900; RCT&#xb97c; &#xcc3e;&#xc9c0; &#xbabb;&#xd588;&#xb2e4;. &#xc5f0;&#xad6c;&#xc9c4; &#xacb0;&#xb860;: &#xacb0;&#xacfc; &#xce21;&#xc815;&#xc5d0; &#xb300;&#xd574; &#xc7a5;&#xb0b4; &#xd29c;&#xbe0c; &#xc601;&#xc591;&#xc774; &#xacbd;&#xad6c; &#xc601;&#xc591;&#xc758; &#xc9c0;&#xc18d;&#xacfc; &#xbe44;&#xad50;&#xd558;&#xc5ec; &#xd6a8;&#xacfc;&#xc801;&#xc778;&#xc9c0; &#xc5ec;&#xbd80;&#xb97c; &#xb098;&#xd0c0;&#xb0b4;&#xb294; RCT &#xb610;&#xb294; &#xc900; RCT&#xb294; &#xc5c6;&#xb2e4;. &#xc774;&#xb7ec;&#xd55c; RCT&#xb294; &#xc724;&#xb9ac;&#xc801; &#xc774;&#xc720;&#xb85c; &#xc218;&#xd589;&#xb420; &#xac00;&#xb2a5;&#xc131;&#xc774; &#xb9e4;&#xc6b0; &#xb0ae;&#xb2e4;. ALS &#xc0bc;&#xd0b4;&#xace4;&#xb780; &#xd658;&#xc790;&#xc758; &#xc0dd;&#xc874;&#xacfc; &#xc0b6;&#xc758; &#xc9c8;&#xc5d0; &#xb300;&#xd55c; &#xb2e4;&#xc591;&#xd55c; &#xacbd;&#xc7a5; &#xc601;&#xc591; &#xc0bd;&#xc785; &#xae30;&#xc220; &#xbc0f; &#xd29c;&#xbe0c; &#xc704;&#xce58; &#xc2dc;&#xae30;&#xc758; &#xd6a8;&#xacfc;&#xb97c; &#xd3c9;&#xac00;&#xd558;&#xb294; RCT&#xac00; &#xc2e4;&#xd604; &#xac00;&#xb2a5;&#xd558;&#xace0; &#xd0c0;&#xb2f9;&#xd558;&#xb2e4;.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd.</CopyrightInformation></OtherAbstract><CoiStatement>AS: none known. AA: none known. AA is a specialist in neurology and manages patients with neuromuscular disorders. EF: none known. BR: none known. BR is a specialist in Physical Medicine and Rehabilitation and manages patients with neurological disorders, including motor neuron disease. LZ: declares consultancy fees from Amylyx, Biogen Idec, and Mitsubishi Tanabe Pharma America, Inc.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>16</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>14</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>14</Day><Hour>14</Hour><Minute>52</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37579081</ArticleId><ArticleId IdType="pmc">PMC10413437</ArticleId><ArticleId IdType="doi">10.1002/14651858.CD004030.pub4</ArticleId></ArticleIdList><ReferenceList><Title>Additional references</Title><ReferenceList><Title>Abdul Aziz 2020</Title><Reference><Citation>Abdul Aziz NA, Toh TH, Goh KJ, Loh EC, Capelle DP, Abdul Latif L, et al. Natural history and clinical features of ALS in Malaysia. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 2020;22(1-2):108-16.</Citation><ArticleIdList><ArticleId IdType="pubmed">33084408</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Allen 2013</Title><Reference><Citation>Allen JA, Chen R, Ajroud-Driss S, Sufit RL, Heller S, Siddique T, et al. Gastrostomy tube placement by endoscopy versus radiologic methods in patients with ALS: A retrospective study of complications and outcome. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 2013;14(4):308-14.</Citation><ArticleIdList><ArticleId IdType="pubmed">23286755</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Allison 2000</Title><Reference><Citation>Allison SP, Rawlings J, Field J, Bean N, Stephen AD. Nutrition in the elderly hospital patient - Nottingham studies. Journal of Nutrition, Health &amp; Aging 2000;4(1):54-7. [PMID: ]</Citation><ArticleIdList><ArticleId IdType="pubmed">10840479</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Andersen 2018</Title><Reference><Citation>Andersen PM, Kuzma-Kozakiewicz M, Keller J, Aho-Oezhan HEA, Ciecwierska K, Szejko N, et al. Therapeutic decisions in ALS patients: cross-cultural differences and clinical implications. Journal of Neurology 2018;265(7):1600-6.</Citation><ArticleIdList><ArticleId IdType="pubmed">29728768</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Atassi 2011</Title><Reference><Citation>Atassi N, Cudkowicz ME, Schoenfeld DA. Advanced statistical methods to study the effects of gastric tube and non-invasive ventilation on functional decline and survival in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis 2011;12(4):272-7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3138079</ArticleId><ArticleId IdType="pubmed">21554030</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Bak 1994</Title><Reference><Citation>Bak S, Bak L. Symptomatic treatment of amyotrophic lateral sclerosis [Symptomatisk behandling af amyotrofisk lateralsklerose]. Ugeskrift for Laeger 1994;156(28):4138-40. [PMID: ]</Citation><ArticleIdList><ArticleId IdType="pubmed">7520644</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Bergner 1981</Title><Reference><Citation>Bergner M, Bobbitt RA, Carter WB, Gilson BS. The Sickness Impact Profile: development and final revision of a health status measure. Medical Care 1981;19(8):787-805.</Citation><ArticleIdList><ArticleId IdType="pubmed">7278416</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Blondet 2010</Title><Reference><Citation>Blondet A, Lebigot J, Nicolas G, Boursier J, Person B, Laccoureye L, et al. Radiologic versus endoscopic placement of percutaneous gastrostomy in amyotrophic lateral sclerosis: multivariate analysis of tolerance, efficacy, and survival. Journal of Vascular and Interventional Radiology 2010;21(4):527-33.</Citation><ArticleIdList><ArticleId IdType="pubmed">20172742</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Boitano 2001</Title><Reference><Citation>Boitano LJ, Jordan T, Benditt JO. Noninvasive ventilation allows gastrostomy tube placement in patients with advanced ALS. Neurology 2001;56(3):413-4. [PMID: ]</Citation><ArticleIdList><ArticleId IdType="pubmed">11171915</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Bond 2019</Title><Reference><Citation>Bond L, Ganguly P, Khamankar N, Mallet N, Bowen G, Green B, et al. A comprehensive examination of percutaneous endoscopic gastrostomy and its association with amyotrophic lateral sclerosis patient outcomes. Brain Sciences 2019;9(9):223.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6770872</ArticleId><ArticleId IdType="pubmed">31487846</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Bond 2020</Title><Reference><Citation>Bond L, Bowen G, Mertens B, Denson K, Jordan K, Vidakovic B, et al. Associations of patient mood, modulators of quality of life, and pharmaceuticals with amyotrophic lateral sclerosis survival duration. Behavioral Sciences 2020;10(1):33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7016647</ArticleId><ArticleId IdType="pubmed">31936812</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Boutron 2021</Title><Reference><Citation>Boutron I, Page MJ, Higgins JP, Altman DG, Lundh A, Hr&#xf3;bjartsson A. Chapter 7: Considering bias and conflicts of interest among the included studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook.</Citation></Reference></ReferenceList><ReferenceList><Title>Bradley 2004</Title><Reference><Citation>Bradley WG, Anderson F, Gowda N, Miller RG, ALS CARE Study Group. Changes in the management of ALS since the publication of the AAN ALS Practice Parameter 1999. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders 2004;5(4):240-4. [PMID: ]</Citation><ArticleIdList><ArticleId IdType="pubmed">15799554</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Braga 2020</Title><Reference><Citation>Braga AC, Gromicho M, Pinto S, Carvalho M, Henning F. A comparative study of South African and Portuguese amyotrophic lateral sclerosis cohorts. Journal of the Neurological Sciences 2020;414:116857.</Citation><ArticleIdList><ArticleId IdType="pubmed">32339966</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Brooks 1994</Title><Reference><Citation>Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on motor neuron diseases/amyotrophic lateral sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial 'Clinical limits of ALS' Workshop Contributors. Journal of the Neurological Sciences 1994 Suppl;124:96-107.</Citation><ArticleIdList><ArticleId IdType="pubmed">7807156</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Brooks 2000</Title><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL, World Federation of Neurology Research Group on Motor Neuron Disease. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders 2000;1:293-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Burkhardt 2017</Title><Reference><Citation>Burkhardt C, Neuwirth C, Sommacal A, Andersen PM, Weber M. Is survival improved by the use of NIV and PEG in amyotrophic lateral sclerosis (ALS)? A post-mortem study of 80 ALS patients. PLOS ONE 2017;12(5):e0177555.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5441602</ArticleId><ArticleId IdType="pubmed">28542233</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Cedarbaum 1999</Title><Reference><Citation>Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. Journal of the Neurological Sciences 1999;169(1):13-21.</Citation><ArticleIdList><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Chavada 2010</Title><Reference><Citation>Chavada G, El-Nayal A, Lee F, Webber SJ, McAlindon M, Walsh T, et al. Evaluation of two different methods for per-oral gastrostomy tube placement in patients with motor neuron disease (MND): PIG versus PEG procedures. Amyotrophic Lateral Sclerosis 2010;11(6):531-6.</Citation><ArticleIdList><ArticleId IdType="pubmed">20553092</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Chhetri 2016</Title><Reference><Citation>Chhetri SK, Bradley BF, Majeed T, Lea RW. Motor neurone disease in Lancashire and South Cumbria in North West England and an 8-year experience with enteral nutrition. Journal of Clinical Neuroscience 2016;24:47-51.</Citation><ArticleIdList><ArticleId IdType="pubmed">26521757</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Chi&#xf2; 1999</Title><Reference><Citation>Chi&#xf2; A, Finocchiaro E, Meineri P, Bottacchi E, Schiffer D. Safety and factors related to survival after percutaneous endoscopic gastrostomy in ALS. ALS Percutaneous Endoscopic Gastrostomy Study Group. Neurology 1999;53(5):1123-5.</Citation><ArticleIdList><ArticleId IdType="pubmed">10496278</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Chi&#xf2; 2002</Title><Reference><Citation>Chi&#xf2; A, Mora G, Leone M, Mazzini L, Cocito D, Giordana MT, et al. Early symptom progression rate is related to ALS outcome: a prospective population-based study. Neurology 2002;59(1):99-103.</Citation><ArticleIdList><ArticleId IdType="pubmed">12105314</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Chi&#xf2; 2004</Title><Reference><Citation>Chi&#xf2; A, Galletti R, Finocchiaro C, Righi D, Ruffino MA, Calvo A, et al. Percutaneous radiological gastrostomy: a safe and effective method of nutritional tube placement in advanced ALS. Journal of Neurology, Neurosurgery and Psychiatry 2004;75(4):645-7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1739007</ArticleId><ArticleId IdType="pubmed">15026518</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Chi&#xf2; 2006</Title><Reference><Citation>Chi&#xf2; A, Bottacchi E, Buffa C, Mutani R, Mora G, PARALS. Positive effects of tertiary centres for amyotrophic lateral sclerosis on outcome and use of hospital facilities. Journal of Neurology, Neurosurgery and Psychiatry 2006;77(8):948-50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2077622</ArticleId><ArticleId IdType="pubmed">16614011</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Czaplinski 2006</Title><Reference><Citation>Czaplinski A, Yen AA, Simpson EP, Appel SH. Slower disease progression and prolonged survival in contemporary patients with amyotrophic lateral sclerosis: is the natural history of amyotrophic lateral sclerosis changing? Archives of Neurology 2006;63(8):1139-43.</Citation><ArticleIdList><ArticleId IdType="pubmed">16908741</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Deeks 2021</Title><Reference><Citation>Deeks JJ, Higgins JP, Altman DG (editors). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook.</Citation></Reference></ReferenceList><ReferenceList><Title>Desport 2000</Title><Reference><Citation>Desport JC, Preux PM, Truong CT, Courat L, Vallat JM, Couratier P. Nutritional assessment and survival in ALS patients. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders 2000;1(2):91-6.</Citation><ArticleIdList><ArticleId IdType="pubmed">11467055</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Desport 2005</Title><Reference><Citation>Desport JC, Mabrouk T, Bouillet P, Perna A, Preux PM, Couratier P. Complications and survival following radiologically and endoscopically-guided gastrostomy in patients with amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis 2005;6(2):88-93.</Citation><ArticleIdList><ArticleId IdType="pubmed">16036431</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>EFNS&#xa0;2012</Title><Reference><Citation>The EFNS Task Force on Diagnosis and Management of Amyotrophic Lateral Sclerosis: Andersen PM, Abrahams S, Borasio GD, Carvalho M, Chio A, Van Damme P, et al. EFNS guidelines on the Clinical Management of Amyotrophic Lateral Sclerosis (MALS) &#x2013; revised report of an EFNS task force. European Journal of Neurology 2012;19:360-75.</Citation><ArticleIdList><ArticleId IdType="pubmed">21914052</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Fasano 2017</Title><Reference><Citation>Fasano A, Fini N, Ferraro D, Ferri L, Vinceti M, Errals, et al. Percutaneous endoscopic gastrostomy, body weight loss and survival in amyotrophic lateral sclerosis: a population-based registry study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 2017;18(3-4):233-42.</Citation><ArticleIdList><ArticleId IdType="pubmed">28076984</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Fini 2014</Title><Reference><Citation>Fini N, Georgoulopoulou E, Vinceti M, Monelli M, Pinelli G, Vacondio P, et al. Noninvasive and invasive ventilation and enteral nutrition for ALS in Italy: management of ALS in Italy. Muscle &amp; Nerve 2014;50(4):508-16.</Citation><ArticleIdList><ArticleId IdType="pubmed">24448736</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Forbes 2004</Title><Reference><Citation>Forbes RB, Colville S, Swingler RJ, Scottish Motor Neurone Disease Research Group. Frequency, timing and outcome of gastrostomy tubes for amyotrophic lateral sclerosis/motor neurone disease - a record linkage study from the Scottish Motor Neurone Disease Register. Journal of Neurology 2004;251(7):813-7.</Citation><ArticleIdList><ArticleId IdType="pubmed">15258782</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>GRADEpro GDT [Computer program]</Title><Reference><Citation>GRADEpro GDT. Version accessed 23 August 2021. Hamilton (ON): McMaster University (developed by Evidence Prime). Available at gradepro.org.</Citation></Reference></ReferenceList><ReferenceList><Title>Gregory 2002</Title><Reference><Citation>Gregory S, Siderowf A, Golaszewski AL, McCluskey L. Gastrostomy insertion in ALS patients with low vital capacity: respiratory support and survival. Neurology 2002;58(3):485-7.</Citation><ArticleIdList><ArticleId IdType="pubmed">11839859</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Higgins 2003</Title><Reference><Citation>Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC192859</ArticleId><ArticleId IdType="pubmed">12958120</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Higgins 2021a</Title><Reference><Citation>Higgins JPT, Savovi&#x107; J, Page MJ, Elbers RG, Sterne JAC. Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook.</Citation></Reference></ReferenceList><ReferenceList><Title>Higgins 2021b</Title><Reference><Citation>Higgins JP, Eldridge S, Li T (editors). Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook.</Citation></Reference></ReferenceList><ReferenceList><Title>Hodgkinson 2018</Title><Reference><Citation>Hodgkinson VL, Lounsberry J, Mirian A, Genge A, Benstead T, Briemberg H, et al. Provincial Differences in the Diagnosis and Care of Amyotrophic Lateral Sclerosis. Canadian Journal of Neurological Sciences/Journal Canadien des Sciences Neurologiques 2018;45(6):652-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">30430962</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Jackson&#x2010;Tarlton 2016</Title><Reference><Citation>Jackson-Tarlton CS, Benstead TJ, Doucette S, CNDR INVESTIGATOR NETWORK. Correlating factors in the recommendation of feeding tubes in the nutritional management of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 2016;17(7-8):515-21.</Citation><ArticleIdList><ArticleId IdType="pubmed">27534658</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Jim&#xe9;nez 2015</Title><Reference><Citation>Jim&#xe9;nez Garc&#xed;a I, Sala Moya N, Riera Munt M, Herrera Rodr&#xed;guez MV, Povedano Panad&#xe9;s M, Virgili Casas MN. The Patient's Opinion Matters: Exeprience in the Nutritional Care in ALS Multidisciplinary Team [La opini&#xf3;n del paciente cuenta: Experiencia en la atenci&#xf3;n nutricional en un equipo multidisciplinar de ELA]. Nutrici&#xf3;n Hospitalaria 2015;31 Suppl 5:56-66.</Citation><ArticleIdList><ArticleId IdType="pubmed">25938606</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Kak 2017</Title><Reference><Citation>Kak M, Issa NP, Roos RP, Sweitzer BJ, Gottlieb O, Guralnick A, et al. Gastrostomy tube placement is safe in advanced amyotrophic lateral sclerosis. Neurological Research 2017;39(1):16-22.</Citation><ArticleIdList><ArticleId IdType="pubmed">27876446</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Karitzky 2001</Title><Reference><Citation>Karitzky J, Ludolph AC. Imaging and neurochemical markers for diagnosis and disease progression in ALS. Journal of the Neurological Sciences 2001;191(1-2):35-41.</Citation><ArticleIdList><ArticleId IdType="pubmed">11676990</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Kasarskis 1999</Title><Reference><Citation>Kasarskis EJ, Scarlata D, Hill R, Fuller C, Stambler N, Cedarbaum JM. A retrospective study of percutaneous endoscopic gastrostomy in ALS patients during the BDNF and CNTF trials. Journal of the Neurological Sciences 1999;169(1-2):118-25.</Citation><ArticleIdList><ArticleId IdType="pubmed">10540019</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Kirstein 2018</Title><Reference><Citation>Kirstein MM, K&#xf6;rner S, Schneider A, Manns MP, Petri S, Voigtl&#xe4;nder T. Percutaneous endoscopic gastrostomy with and without jejunal extension in patients with amyotrophic lateral sclerosis. European Journal of Gastroenterology &amp; Hepatology 2018;30(3):257-62.</Citation><ArticleIdList><ArticleId IdType="pubmed">29324589</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Klav&#x17e;ar 2020</Title><Reference><Citation>Klav&#x17e;ar P, Koritnik B, Leonardis L, Dolenc Gro&#x161;elj L, Kirbi&#x161; M, et al. Improvements in the multidisciplinary care are beneficial for survival in amyotrophic lateral sclerosis (ALS): experience from a tertiary ALS center. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 2020;21(3-4):203-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">32248716</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Klor 1999</Title><Reference><Citation>Klor BM, Milianti FJ. Rehabilitation of neurogenic dysphagia with percutaneous endoscopic gastrostomy. Dysphagia 1999;14(3):162-4.</Citation><ArticleIdList><ArticleId IdType="pubmed">10341114</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Lechtzin 2001</Title><Reference><Citation>Lechtzin N, Wiener CM, Clawson L, Chaudhry V, Diette GB. Hospitalization in amyotrophic lateral sclerosis: causes, costs and outcomes. Neurology 2001;56(6):753-7.</Citation><ArticleIdList><ArticleId IdType="pubmed">11274310</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Lee 2013</Title><Reference><Citation>Lee CTC, Chiu YW, Wang KC, Hwang CS, Lin KH, Lee IT, et al. Riluzole and prognostic factors in amyotrophic lateral sclerosis long-term and short-term survival: a population-based study of 1149 cases in Taiwan. Journal of Epidemiology 2013;23(1):35-40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3700231</ArticleId><ArticleId IdType="pubmed">23117224</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Limousin 2010</Title><Reference><Citation>Limousin N, Blasco H, Corcia P, Gordon PH, De Toffol B, Andres C, et al. Malnutrition at the time of diagnosis is associated with a shorter disease duration in ALS. Journal of the Neurological Sciences 2010;297(1-2):36-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">20673675</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Lindauer 2013</Title><Reference><Citation>Lindauer E, Dupuis L, Muller HP, Neumann H, Ludolph AC, Kassubek J. Adipose Tissue Distribution Predicts Survival in Amyotrophic Lateral Sclerosis. PLoS One 2013;8(6):e67783.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3694869</ArticleId><ArticleId IdType="pubmed">23826340</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Longinetti 2018</Title><Reference><Citation>Longinetti E, Regod&#xf3;n Wallin A, Samuelsson K, Press R, Zachau A, Ronnevi LO, et al. The Swedish motor neuron disease quality registry. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 2018;19(7-8):528-37.</Citation><ArticleIdList><ArticleId IdType="pubmed">30296856</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Mandrioli 2018</Title><Reference><Citation>Mandrioli J, Malerba SA, Beghi E, Fini N, Fasano A, Zucchi E, et al. Riluzole and other prognostic factors in ALS: a population-based registry study in Italy. Journal of Neurology 2018;265(4):817-27.</Citation><ArticleIdList><ArticleId IdType="pubmed">29404735</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Marin 2011</Title><Reference><Citation>Marin B, Desport JC, Kajeu P, Jesus P, Nicolaud B, Nicol M, Preux PM, Couratier P. Alteration of nutritional status at diagnosis is a prognostic factor for survival of amyotrophic lateral sclerosis patients. Journal of Neurology, Neurosurgery and Psychiatry 2011;82(6):628-34.</Citation><ArticleIdList><ArticleId IdType="pubmed">21097551</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Mazzini 1995</Title><Reference><Citation>Mazzini L, Corra T, Zaccala M, Mora G, Del Piano M, Galante M. Percutaneous endoscopic gastrostomy and enteral nutrition in amyotrophic lateral sclerosis. Journal of Neurology 1995;242(10):695-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">8568533</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>McDonnell 2017</Title><Reference><Citation>McDonnell E, Schoenfeld D, Paganoni S, Atassi N. Causal inference methods to study gastric tube use in amyotrophic lateral sclerosis. Neurology 2017-10-03;89(14):1483-9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5631169</ArticleId><ArticleId IdType="pubmed">28864675</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Miller 1999</Title><Reference><Citation>Miller RG, Rosenberg JA, Gelinas DF, Mitsumoto H, Newman D, Sufit R, et al. Practice parameter: the care of the patient with amyotrophic lateral sclerosis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology: ALS Practice Parameters Task Force. Neurology 1999;52(7):1311-23. [MEDLINE: ]</Citation><ArticleIdList><ArticleId IdType="pubmed">10227612</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Miller 2009</Title><Reference><Citation>Miller RG, Jackson CE, Kasarskis EJ, England JD, Forshew D, Johnston W, et al. Practice Parameter update: The care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2009;73(15):1218-26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2764727</ArticleId><ArticleId IdType="pubmed">19822872</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Mitchell 2006</Title><Reference><Citation>Mitchell JD, O'Brien MR, Joshi M. Audit of outcomes in motor neuron disease (MND) patients treated with riluzole. Amyotrophic Lateral Sclerosis 2006;7(2):67-71.</Citation><ArticleIdList><ArticleId IdType="pubmed">16753969</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Mitsumoto 2003</Title><Reference><Citation>Mitsumoto H, Davidson M, Moore D, Gad N, Brandis M, Ringel S, et al. Percutaneous endoscopic gastrostomy (PEG) in patients with ALS and bulbar dysfunction. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders 2003;4(3):177-85.</Citation><ArticleIdList><ArticleId IdType="pubmed">13129795</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Murphy 2008</Title><Reference><Citation>Murphy M, Quinn S, Young J, Parkin P, Taylor B. Increasing incidence of ALS in Canterbury, New Zealand: a 22-year study. Neurology 2008;71(23):1889-95.</Citation><ArticleIdList><ArticleId IdType="pubmed">19047561</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Neudert 2001</Title><Reference><Citation>Neudert C, Oliver D, Wasner M, Borasio GD. The course of the terminal phase in patients with amyotrophic lateral sclerosis. Journal of Neurology 2001;248(7):612-6.</Citation><ArticleIdList><ArticleId IdType="pubmed">11518004</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>O'Boyle 1994</Title><Reference><Citation>O'Boyle CA. The Schedule for the Evaluation of Individual Quality of Life (SEIQoL): the concept of quality of life in clinical research. International Journal of Mental Health 1994;23(3):3-23.</Citation></Reference></ReferenceList><ReferenceList><Title>Oliver 2010</Title><Reference><Citation>Oliver DJ, Turner MR. Some difficult decisions in ALS/MND. Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases 2010;11(4):339-43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3182548</ArticleId><ArticleId IdType="pubmed">20550485</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Paipa 2019</Title><Reference><Citation>Paipa AJ, Povedano M, Barcelo A, Dom&#xed;nguez R, Saez M, Turon J, et al. Survival benefit of multidisciplinary care in amyotrophic lateral sclerosis in Spain: association with noninvasive mechanical ventilation. Journal of Multidisciplinary Healthcare 2019;12:465-70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6590410</ArticleId><ArticleId IdType="pubmed">31354285</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>RevMan Web 2022 [Computer program]</Title><Reference><Citation>Review Manager Web (RevMan Web). Version 4.12.0. The Cochrane Collaboration, 2022. Available at revman.cochrane.org.</Citation></Reference></ReferenceList><ReferenceList><Title>Rio 2010</Title><Reference><Citation>Rio A, Ellis C, Shaw C, Willey E, Ampong M-A, Wijesekera L, et al. Nutritional factors associated with survival following enteral tube feeding in patients with motor neurone disease: complications following gastrostomy insertion. Journal of Human Nutrition and Dietetics 2010;23(4):408-15.</Citation><ArticleIdList><ArticleId IdType="pubmed">20487174</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Sch&#xfc;nemann 2021a</Title><Reference><Citation>Sch&#xfc;nemann HJ, Higgins JP, Vist GE, Glasziou P, Akl EA, Skoetz N, Guyatt GH. Chapter 14: Completing &#x2018;Summary of findings&#x2019; tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook.</Citation></Reference></ReferenceList><ReferenceList><Title>Sch&#xfc;nemann 2021b</Title><Reference><Citation>Sch&#xfc;nemann HJ, Vist GE, Higgins JP, Santesso N, Deeks JJ, Glasziou P, et al. Chapter 15: Interpreting results and drawing conclusions. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook.</Citation></Reference></ReferenceList><ReferenceList><Title>Seki 2000</Title><Reference><Citation>Seki H, Kameya T, Kimura I. A survey of current nutrition therapy for the ALS patients in Japanese national sanatoriums. Rinsho Shinkeigaku - Clinical Neurology 2000;40(11):1083-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">11332187</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Shaw 2006</Title><Reference><Citation>Shaw AS, Ampong MA, Rio A, Al-Chalabi A, Sellars ME, Ellis C, et al. Survival of patients with ALS following institution of enteral feeding is related to pre&#x2010;procedure oximetry: a retrospective review of 98 patients in a single centre. Amyotrophic Lateral Sclerosis 2006;7(1):16-21.</Citation><ArticleIdList><ArticleId IdType="pubmed">16546754</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Shoesmith 2020</Title><Reference><Citation>Shoesmith C, Abrahao A, Benstead T, Chum M, Dupre N, Izenberg A, et al. Canadian best practice recommendations for the management of amyotrophic lateral sclerosis. Canadian Medical Association Journal 2020;192(46):E1453-68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7683000</ArticleId><ArticleId IdType="pubmed">33199452</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Silani 1998</Title><Reference><Citation>Silani V, Kasarskis EJ, Yanagisawa N. Nutritional management in amyotrophic lateral sclerosis: a worldwide perspective. Journal of Neurology 1998;245(Suppl 2):S13-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">9747929</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Simmons 2006</Title><Reference><Citation>Simmons Z, Felgoise SH, Bremer BA, Walsh SM, Hufford DJ, Bromberg MB, et al. The ALSSQOL: balancing physical and nonphysical factors in assessing quality of life in ALS. Neurology 2006;67(9):1659-64.</Citation><ArticleIdList><ArticleId IdType="pubmed">17101900</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Sorenson 2007</Title><Reference><Citation>Sorenson EJ, Crum B, Stevens JC. Incidence of aspiration pneumonia in ALS in Olmsted County, MN. Amyotrophic Lateral Sclerosis 2007;8(2):87-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">17453635</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Spataro 2011</Title><Reference><Citation>Spataro R, Ficano L, Piccoli F, La Bella V. Percutaneous endoscopic gastrostomy in amyotrophic lateral sclerosis: Effect on survival. Journal of the Neurological Sciences 2011;304(1-2):44-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">21371720</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Stavroulakis 2013</Title><Reference><Citation>Stavroulakis T, Walsh T, Shaw PJ, McDermott CJ. Gastrostomy use in motor neurone disease (MND): a review, meta-analysis and survey of current practice. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 2013;14(2):96-104.</Citation><ArticleIdList><ArticleId IdType="pubmed">22985431</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Strong 1999</Title><Reference><Citation>Strong MJ, Rowe A, Rankin RN. Percutaneous gastrojejunostomy in amyotrophic lateral sclerosis. Journal of the Neurological Sciences 1999;169(1-2):128-32.</Citation><ArticleIdList><ArticleId IdType="pubmed">10540021</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>S&#xe1;nchez&#x2010;Mart&#xed;nez 2019</Title><Reference><Citation>S&#xe1;nchez-Mart&#xed;nez CM, Chore&#xf1;o-Parra JA, Nu&#xf1;ez-Orozco L, Placencia-&#xc1;lvarez N, Alvis-Casta&#xf1;o LM, Guadarrama-Ortiz P. A retrospective study of the clinical phenotype and predictors of survival in non-Caucasian Hispanic patients with amyotrophic lateral sclerosis. BMC Neurology 2019;19(1):261.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6819359</ArticleId><ArticleId IdType="pubmed">31664949</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Talman 2016</Title><Reference><Citation>Talman P, Duong T, Vucic S, Mathers S, Venkatesh S, Henderson R, et al. Identification and outcomes of clinical phenotypes in amyotrophic lateral sclerosis/motor neuron disease: Australian National Motor Neuron Disease observational cohort. BMJ Open 2016;6(9):e012054.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5051496</ArticleId><ArticleId IdType="pubmed">27694488</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Thornton 2002</Title><Reference><Citation>Thornton FJ, Fotheringham T, Alexander M, Hardiman O, McGrath FP, Lee MJ. Amyotrophic lateral sclerosis: enteral nutrition provision - endoscopic or radiologic gastrostomy? Radiology 2002;224(3):713-7.</Citation><ArticleIdList><ArticleId IdType="pubmed">12202704</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Van Es 2017</Title><Reference><Citation>Van Es MA, Hardiman O, Chio A, Al-Chalabi A, Pasterkamp RJ, Veldink JH, et al. Amyotrophic Lateral Sclerosis. Lancet 2017;390(10107):2084-98.</Citation><ArticleIdList><ArticleId IdType="pubmed">28552366</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Vergonjeanne 2020</Title><Reference><Citation>Vergonjeanne M, Fayemendy P, Marin B, Penoty M, Lautrette G, Sourisseau H, et al. Predictive factors for gastrostomy at time of diagnosis and impact on survival in patients with amyotrophic lateral sclerosis. Clinical Nutrition 2020;39(10):3112-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">32063408</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Yanagisawa 1996</Title><Reference><Citation>Yanagisawa N, Shindo M. Nationwide study on the natural course of amyotrophic lateral sclerosis in Japan. Annual report of the Research Committee of CNS Degenerative Diseases, Ministry of Health and Welfare in Japan for the year 1995. Matsumoto 1996:253-5.</Citation></Reference></ReferenceList><ReferenceList><Title>Yuan 2020</Title><Reference><Citation>Yuan TW, He Y, Wang SB, Kong P, Cao J. Technical success rate and safety of radiologically inserted gastrostomy versus percutaneous endoscopic gastrostomy in motor neuron disease patients undergoing: a systematic review and meta-analysis. Journal of the Neurological Sciences 2020;410:116622.</Citation><ArticleIdList><ArticleId IdType="pubmed">31884351</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Zhang 2012</Title><Reference><Citation>Zhang L, Sanders L, Fraser RJ. Nutritional support teams increase percutaneous endoscopic gastrostomy uptake in motor neuron disease. World Journal of Gastroenterology : WJG 2012;18(44):6461-7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3508641</ArticleId><ArticleId IdType="pubmed">23197892</ArticleId></ArticleIdList></Reference></ReferenceList></ReferenceList><ReferenceList><Title>References to other published versions of this review</Title><ReferenceList><Title>Katzberg 2011</Title><Reference><Citation>Katzberg HD, Benatar M. Enteral tube feeding for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Systematic Reviews 2011, Issue 1. Art. No: CD004030. [DOI: 10.1002/14651858.CD004030.pub3]</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD004030.pub3</ArticleId><ArticleId IdType="pmc">PMC7163276</ArticleId><ArticleId IdType="pubmed">21249659</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Langmore 2003</Title><Reference><Citation>Langmore S, Kasarskis E, Manca ML, Olney R. Enteral feeding for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Systematic Reviews 2003, Issue 1. Art. No: CD004030. [DOI: 10.1002/14651858.CD004030]</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD004030</ArticleId><ArticleId IdType="pubmed">17054194</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Langmore 2006</Title><Reference><Citation>Langmore SE, Kasarskis EJ, Manca ML, Olney RK. Enteral tube feeding for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Systematic Reviews 2006, Issue 4. Art. No: CD004030. [DOI: 10.1002/14651858.CD004030.pub2]</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD004030.pub2</ArticleId><ArticleId IdType="pubmed">17054194</ArticleId></ArticleIdList></Reference></ReferenceList></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>